Anixa Biosciences (ANIX)
(Delayed Data from NSDQ)
$3.15 USD
-0.11 (-3.37%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $3.18 +0.03 (0.95%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ANIX 3.15 -0.11(-3.37%)
Will ANIX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ANIX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANIX
Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year?
Is Anixa Biosciences (ANIX) Outperforming Other Medical Stocks This Year?
ANIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
ANIXA BIOSCIENCES INC (ANIX) is a Great Momentum Stock: Should You Buy?
Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year?
What Makes ANIXA BIOSCIENCES INC (ANIX) a Strong Momentum Stock: Buy Now?
Other News for ANIX
ANIX: D. Boral Capital Reaffirms 'Buy' Rating with $10 Price Target | ANIX Stock News
Insider Buying: Titterton Lewis H jr Acquires Additional Shares of Anixa Biosciences Inc (ANIX)
Anixa Biosciences (ANIX) Advances Breast Cancer Vaccine to Phase 2 Trials
Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming ...
Anixa plans to begin Phase 2 of breast cancer vaccine trial